{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T18:54:45Z","timestamp":1794423285116,"version":"4.9.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U01NS093334"],"award-info":[{"award-number":["U01NS093334"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG053798"],"award-info":[{"award-number":["R01AG053798"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P20AG068053"],"award-info":[{"award-number":["P20AG068053"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG072959"],"award-info":[{"award-number":["P30AG072959"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R35AG71476"],"award-info":[{"award-number":["R35AG71476"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ted and Maria Quirk Endowment"},{"name":"Joy Chambers-Grundy Endowment"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40259-023-00633-2","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T11:01:55Z","timestamp":1699873315000},"page":"5-22","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":379,"title":["Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-4158","authenticated-orcid":false,"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M. Leisgang","family":"Osse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis","family":"Cammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayde","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"issue":"5","key":"633_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"VL Feigin","year":"2019","unstructured":"Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459\u201380.","journal-title":"Lancet Neurol"},{"issue":"2","key":"633_CR2","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis."},{"issue":"1","key":"633_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimer\u2019s Res Ther. 2021;13(1):80.","journal-title":"Alzheimer\u2019s Res Ther."},{"issue":"1","key":"633_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"18","key":"633_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"issue":"4","key":"633_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimer\u2019s Dementia. 2011;7(4):367\u201385.","journal-title":"Alzheimer\u2019s Dementia."},{"issue":"2","key":"633_CR7","first-page":"221","volume":"9","author":"J Cummings","year":"2022","unstructured":"Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9(2):221\u201330.","journal-title":"J Prev Alzheimers Dis."},{"issue":"3","key":"633_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362\u201377. https:\/\/doi.org\/10.14283\/jpad.2023.30.","journal-title":"J Prev Alzheimers Dis."},{"issue":"1","key":"633_CR9","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","volume":"8","author":"JW Arndt","year":"2018","unstructured":"Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2. Sci Rep. 2018;8(1):6412.","journal-title":"Sci Rep"},{"issue":"1","key":"633_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L S\u00f6derberg","year":"2023","unstructured":"S\u00f6derberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, aducanumab, and gantenerumab\u2014binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease. Neurotherapeutics. 2023;20(1):195\u2013206.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"633_CR11","doi-asserted-by":"publisher","first-page":"31925","DOI":"10.52965\/001c.31925","volume":"10","author":"HW Haddad","year":"2022","unstructured":"Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye AM, Kaye AD. Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer\u2019s disease: a comprehensive review. Health Psychol Res. 2022;10(1):31925.","journal-title":"Health Psychol Res"},{"issue":"6740","key":"633_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173.","journal-title":"Nature"},{"issue":"6815","key":"633_CR13","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"D Morgan","year":"2000","unstructured":"Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease. Nature. 2000;408(6815):982\u20135.","journal-title":"Nature"},{"issue":"9","key":"633_CR14","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553\u201362.","journal-title":"Neurology"},{"issue":"1","key":"633_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46\u201354.","journal-title":"Neurology"},{"issue":"11","key":"633_CR16","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","volume":"65","author":"JAR Nicoll","year":"2006","unstructured":"Nicoll JAR, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006;65(11):1040\u20138.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"9634","key":"633_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"C Holmes","year":"2008","unstructured":"Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372(9634):216\u201323.","journal-title":"Lancet"},{"issue":"24","key":"633_CR18","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","volume":"73","author":"S Salloway","year":"2009","unstructured":"Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73(24):2061\u201370.","journal-title":"Neurology"},{"issue":"1","key":"633_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","volume":"8","author":"R Vandenberghe","year":"2016","unstructured":"Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al. Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):18.","journal-title":"Alzheimers Res Ther."},{"issue":"4","key":"633_CR20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):322\u201333.","journal-title":"N Engl J Med"},{"issue":"4","key":"633_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363\u201372.","journal-title":"Lancet Neurol"},{"issue":"4","key":"633_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):311\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"633_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1073858410381532","volume":"17","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Lee DHS. Sink hypothesis and therapeutic strategies for attenuating Abeta levels. Neuroscientist. 2011;17(2):163\u201373.","journal-title":"Neuroscientist"},{"issue":"4","key":"633_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med. 2018;378(4):321\u201330.","journal-title":"N Engl J Med"},{"issue":"21","key":"633_CR25","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","volume":"90","author":"JL Cummings","year":"2018","unstructured":"Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, et al. ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889\u201397.","journal-title":"Neurology"},{"issue":"1","key":"633_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","volume":"10","author":"S Salloway","year":"2018","unstructured":"Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE). Alzheimers Res Ther. 2018;10(1):96.","journal-title":"Alzheimers Res Ther."},{"issue":"11","key":"633_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","volume":"79","author":"S Ostrowitzki","year":"2022","unstructured":"Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 2022;79(11):1113\u201321.","journal-title":"JAMA Neurol"},{"issue":"1","key":"633_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9(1):95.","journal-title":"Alzheimers Res Ther."},{"key":"633_CR29","unstructured":"FDA Office of the Commissioner. FDA. FDA; 2023 [cited 31 May 2023]. FDA Grants Accelerated Approval for Alzheimer\u2019s Disease Treatment. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-disease-treatment"},{"issue":"7618","key":"633_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"key":"633_CR31","unstructured":"Bussiere T, Weinreb PH, Dunstan RW, Qian F, Arastu MF, Li M, et al. Differential in vitro and in vivo binding profiles of BIIB037 and other anti-abeta clinical antibody candidates. Neurodegener Dis. 2013. https:\/\/misc.karger.com\/websites\/NDD_2013_011_s_1\/AbstractCD\/pdf\/787.pdf."},{"key":"633_CR32","unstructured":"Biogen. A randomized, blinded, placebo-controlled single ascending dose study of the safety, tolerability, and pharmacokinetics of biib037 in subjects with mild to moderate Alzheimer\u2019s disease. ClinicalTrials.gov; 2015 Mar [cited 23 Mar 2023]. Report No. NCT01397539. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01397539."},{"issue":"3","key":"633_CR33","first-page":"169","volume":"2","author":"J Ferrero","year":"2016","unstructured":"Ferrero J, Williams L, Stella H, Leitermann K, Mikulskis A, O\u2019Gorman J, et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease. Alzheimer\u2019s Dementia. 2016;2(3):169\u201376.","journal-title":"Alzheimer\u2019s Dementia."},{"key":"633_CR34","unstructured":"Biogen. A randomized, double-blinded, placebo-controlled multiple dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BIIB037 in subjects with prodromal or mild Alzheimer\u2019s disease. ClinicalTrials.gov; 2020 Jul [cited 23 Mar 2023]. Report No. NCT01677572. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01677572."},{"key":"633_CR35","unstructured":"Biogen. A phase 2, multicenter, randomized, parallel-group, double-blind, controlled study of aducanumab (BIIB037) in subjects with mild cognitive impairment due to Alzheimer\u2019s disease or with mild Alzheimer\u2019s disease dementia to evaluate the safety of continued dosing in subjects with asymptomatic amyloid-related imaging abnormalities. ClinicalTrials.gov; 2021 Aug [cited 30 Mar 2023]. Report No. NCT03639987. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03639987."},{"issue":"1","key":"633_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79(1):13\u201321.","journal-title":"JAMA Neurol"},{"key":"633_CR37","unstructured":"Biogen. A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer\u2019s disease. ClinicalTrials.gov; 2021 Aug [cited 30 Mar 2023]. Report No. NCT02477800. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02477800."},{"key":"633_CR38","unstructured":"Biogen. A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer\u2019s disease. ClinicalTrials.gov; 2021 Aug [cited 22 Mar 2023]. Report No. NCT02484547. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02484547."},{"issue":"2","key":"633_CR39","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40120-021-00273-0","volume":"10","author":"WL Herring","year":"2021","unstructured":"Herring WL, Gould IG, Fillit H, Lindgren P, Forrestal F, Thompson R, et al. Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer\u2019s disease. Neurol Ther. 2021;10(2):919\u201340.","journal-title":"Neurol Ther."},{"key":"633_CR40","unstructured":"von Rosenstiel P, Haeberlein SB, Castrillo-Viguera C, Chen T, O\u2019Gorman J, Rajagovindan R, et al. Aducanumab 48-month analyses from PRIME, a phase 1b study in patients with early Alzheimer\u2019s disease. 11th Clinical Trials on Alzheimer\u2019s Disease Congress 2018; 2018 [cited 23 Aug 2023]; Barcelona, Spain. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8571451\/."},{"issue":"1","key":"633_CR41","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","volume":"103","author":"H Englund","year":"2007","unstructured":"Englund H, Sehlin D, Johansson AS, Nilsson LNG, Gellerfors P, Paulie S, et al. Sensitive ELISA detection of amyloid-\u03b2 protofibrils in biological samples. J Neurochem. 2007;103(1):334\u201345.","journal-title":"J Neurochem"},{"key":"633_CR42","unstructured":"FDA Office of the Commissioner. Eisai Newsroom. 2023. FDA Approves LEQEMBI\u2122 (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer\u2019s Disease [cited 31 May 2023]. https:\/\/media-us.eisai.com\/2023-01-06-FDA-Approves-LEQEMBI-TM-lecanemab-irmb-Under-the-Accelerated-Approval-Pathway-for-the-Treatment-of-Alzheimers-Disease."},{"issue":"9","key":"633_CR43","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nn0901-887","volume":"4","author":"C Nilsberth","year":"2001","unstructured":"Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The \u201cArctic\u201d APP mutation (E693G) causes Alzheimer\u2019s disease by enhanced A\u03b2 protofibril formation. Nat Neurosci. 2001;4(9):887\u201393.","journal-title":"Nat Neurosci"},{"issue":"3","key":"633_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.nbd.2009.08.007","volume":"36","author":"A Lord","year":"2009","unstructured":"Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, S\u00f6derberg L, et al. An amyloid-\u03b2 protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis. 2009;36(3):425\u201334.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"633_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032014","volume":"7","author":"D Sehlin","year":"2012","unstructured":"Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, et al. Large aggregates are the major soluble A\u03b2 species in AD brain fractionated with density gradient ultracentrifugation. PLoS ONE. 2012;7(2): e32014.","journal-title":"PLoS ONE"},{"issue":"1","key":"633_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","volume":"8","author":"V Logovinsky","year":"2016","unstructured":"Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, et al. Safety and tolerability of BAN2401\u2014a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody. Alzheimer\u2019s Res Ther. 2016;8(1):14.","journal-title":"Alzheimer\u2019s Res Ther."},{"issue":"1","key":"633_CR47","first-page":"1","volume":"2","author":"A Satlin","year":"2016","unstructured":"Satlin A, Wang J, Logovinsky V, Berry S, Swanson C, Dhadda S, et al. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer\u2019s disease. Alzheimer\u2019s Dementia. 2016;2(1):1\u201312.","journal-title":"Alzheimer\u2019s Dementia."},{"issue":"40","key":"633_CR48","doi-asserted-by":"publisher","first-page":"38194","DOI":"10.1074\/jbc.M303164200","volume":"278","author":"R Rauchenberger","year":"2003","unstructured":"Rauchenberger R, Borges E, Thomassen-Wolf E, Rom E, Adar R, Yaniv Y, et al. Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J Biol Chem. 2003;278(40):38194\u2013205.","journal-title":"J Biol Chem"},{"key":"633_CR49","first-page":"1359","volume":"7","author":"D Novakovic","year":"2013","unstructured":"Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi C, et al. Profile of gantenerumab and its potential in the treatment of Alzheimer\u2019s disease. Drug Des Dev Ther. 2013;7:1359\u201364.","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"633_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-\u03b2. J Alzheimers Dis. 2012;28(1):49\u201369.","journal-title":"J Alzheimers Dis"},{"key":"633_CR51","unstructured":"Hoffmann-La Roche. A single-dose study to investigate the safety, tolerability, and pharmacokinetics (PK) of gantenerumab following subcutaneous (SC) administration in healthy volunteers. ClinicalTrials.gov; 2019 Apr [cited 30 May 2023]. Report No. NCT02711423. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02711423."},{"key":"633_CR52","unstructured":"Hoffmann-La Roche. A multiple ascending dose study of R1450 in patients with Alzheimer disease. ClinicalTrials.gov; 2016 Nov [cited 30 May 2023]. Report No. NCT00531804. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00531804."},{"issue":"2","key":"633_CR53","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","volume":"69","author":"S Ostrowitzki","year":"2012","unstructured":"Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198\u2013207.","journal-title":"Arch Neurol"},{"key":"633_CR54","unstructured":"Hoffmann-La Roche. A study of gantenerumab in participants with prodromal Alzheimer\u2019s disease (Scarlet Road). ClinicalTrials.gov; 2021 Dec [cited 30 May 2023]. Report No. NCT01224106. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01224106."},{"key":"633_CR55","unstructured":"Washington University School of Medicine. Dominantly inherited Alzheimer network trial: an opportunity to prevent dementia. a study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer\u2019s disease caused by a genetic mutation. Master Protocol DIAN-TU-001 (DIAN-TU). ClinicalTrials.gov; 2023 May [cited 30 May 2023]. Report No. NCT01760005. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01760005."},{"issue":"5","key":"633_CR56","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.26511","volume":"92","author":"N Joseph-Mathurin","year":"2022","unstructured":"Joseph-Mathurin N, Llibre-Guerra JJ, Li Y, McCullough AA, Hofmann C, Wojtowicz J, et al. Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease. Ann Neurol. 2022;92(5):729\u201344.","journal-title":"Ann Neurol"},{"key":"633_CR57","unstructured":"Hoffmann-La Roche. Efficacy and safety study of gantenerumab in participants with early Alzheimer\u2019s disease (AD). ClinicalTrials.gov; 2023 Apr [cited 30 May 2023]. Report No. NCT03444870. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03444870."},{"issue":"S9","key":"633_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/alz.052060","volume":"17","author":"F Boess","year":"2021","unstructured":"Boess F, Sakaoka S, Abi-Saab D, Scelsi MA, Delmar P, Hofmann C, et al. Graduation study design: evaluation of once-weekly subcutaneous administration of gantenerumab on brain amyloid load. Alzheimer\u2019s Dementia. 2021;17(S9): e052060.","journal-title":"Alzheimer\u2019s Dementia."},{"issue":"5","key":"633_CR59","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB DeMattos","year":"2012","unstructured":"DeMattos RB, Lu J, Tang Y, Racke MM, DeLong CA, Tzaferis JA, et al. A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice. Neuron. 2012;76(5):908\u201320.","journal-title":"Neuron"},{"issue":"5","key":"633_CR60","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00401-022-02418-3","volume":"143","author":"Y Bouter","year":"2022","unstructured":"Bouter Y, Liekefeld H, Pichlo S, Westhoff AC, Fenn L, Bakrania P, et al. Donanemab detects a minor fraction of amyloid-\u03b2 plaques in post-mortem brain tissue of patients with Alzheimer\u2019s disease and Down syndrome. Acta Neuropathol. 2022;143(5):601\u20133.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"633_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12112","volume":"7","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2021;7(1): e12112.","journal-title":"Alzheimers Dement (N Y)."},{"issue":"4","key":"633_CR62","first-page":"414","volume":"8","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, Duggan Evans C, Shcherbinin S, Cheng YJ, Willis BA, Gueorguieva I, et al. Donanemab (LY3002813) phase 1b study in Alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimers Dis. 2021;8(4):414\u201324.","journal-title":"J Prev Alzheimers Dis."},{"issue":"10","key":"633_CR63","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","volume":"79","author":"S Shcherbinin","year":"2022","unstructured":"Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(10):1015\u201324.","journal-title":"JAMA Neurol"},{"issue":"12","key":"633_CR64","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","volume":"79","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(12):1250\u20139.","journal-title":"JAMA Neurol"},{"key":"633_CR65","unstructured":"Eli Lilly and Company. Lilly\u2014News Release. 2023. Lilly\u2019s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer\u2019s Disease. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-donanemab-significantly-slowed-cognitive-and-functional."},{"issue":"6","key":"633_CR66","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"key":"633_CR67","unstructured":"Eli Lilly and Company. Lilly\u2014News Release. 2023. U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/us-food-and-drug-administration-issues-complete-response-0."},{"key":"633_CR68","unstructured":"Alzforum. 2023. Remternetug [cited 26 Apr 2023]. https:\/\/www.alzforum.org\/therapeutics\/remternetug."},{"key":"633_CR69","unstructured":"Alzforum. 2023. International conference on Alzheimer\u2019s and Parkinson\u2019s diseases 2023: next goals for immunotherapy: make it safer, less of a hassle. https:\/\/www.alzforum.org\/news\/conference-coverage\/next-goals-immunotherapy-make-it-safer-less-hassle."},{"issue":"2","key":"633_CR70","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1517\/17425247.2014.952627","volume":"12","author":"WM Pardridge","year":"2015","unstructured":"Pardridge WM. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv. 2015;12(2):207\u201322.","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"633_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12385","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9(2): e12385.","journal-title":"Alzheimers Dement (N Y)."},{"issue":"7","key":"633_CR72","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","volume":"83","author":"J Cummings","year":"2023","unstructured":"Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics. Drugs. 2023;83(7):569\u201376.","journal-title":"Drugs"},{"issue":"4","key":"633_CR73","first-page":"398","volume":"8","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021;8(4):398\u2013410.","journal-title":"J Prev Alzheimers Dis."},{"issue":"3","key":"633_CR74","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/brain\/awad005","volume":"146","author":"R Perneczky","year":"2023","unstructured":"Perneczky R, Jessen F, Grimmer T, Levin J, Fl\u00f6el A, Peters O, et al. Anti-amyloid antibody therapies in Alzheimer\u2019s disease. Brain. 2023;146(3):842\u20139.","journal-title":"Brain"},{"issue":"1","key":"633_CR75","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3 G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Su\u00e1rez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer\u2019s Res Ther. 2019;11(1):27.","journal-title":"Alzheimer\u2019s Res Ther."},{"issue":"9","key":"633_CR76","doi-asserted-by":"publisher","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","volume":"96","author":"WJ Jagust","year":"2021","unstructured":"Jagust WJ, Landau SM. Temporal dynamics of \u03b2-amyloid accumulation in aging and Alzheimer disease. Neurology. 2021;96(9):e1347\u201357.","journal-title":"Neurology"},{"issue":"4","key":"633_CR77","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.1212\/WNL.0000000000011214","volume":"96","author":"ME Farrell","year":"2021","unstructured":"Farrell ME, Jiang S, Schultz AP, Properzi MJ, Price JC, Becker JA, et al. Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation. Neurology. 2021;96(4):e619\u201331.","journal-title":"Neurology"},{"issue":"9","key":"633_CR78","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, Salvad\u00f3 G, Ortiz-Romero P, Montoliu-Gaya L, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28(9):1797\u2013801.","journal-title":"Nat Med"},{"issue":"7","key":"633_CR79","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00259-021-05191-9","volume":"48","author":"V Dor\u00e9","year":"2021","unstructured":"Dor\u00e9 V, Krishnadas N, Bourgeat P, Huang K, Li S, Burnham S, et al. Relationship between amyloid and tau levels and its impact on tau spreading. Eur J Nucl Med Mol Imaging. 2021;48(7):2225\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"633_CR80","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28(11):2381\u20137.","journal-title":"Nat Med"},{"issue":"4","key":"633_CR81","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357\u201367.","journal-title":"Lancet Neurol"},{"issue":"9","key":"633_CR82","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1056\/NEJMc2111960","volume":"385","author":"B Dunn","year":"2021","unstructured":"Dunn B, Stein P, Temple R, Cavazzoni P. An appropriate use of accelerated approval\u2014aducanumab for Alzheimer\u2019s disease. N Engl J Med. 2021;385(9):856\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"633_CR83","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","volume":"13","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimer\u2019s Res Ther. 2021;13(1):98.","journal-title":"Alzheimer\u2019s Res Ther."},{"issue":"3","key":"633_CR84","doi-asserted-by":"publisher","first-page":"595","DOI":"10.14283\/jpad.2023.50","volume":"10","author":"SP Dickson","year":"2023","unstructured":"Dickson SP, Wessels AM, Dowsett SA, Mallinckrodt C, Sparks JD, Chatterjee S, et al. \u2018Time saved\u2019 as a demonstration of clinical meaningfulness and illustrated using the donanemab TRAILBLAZER-ALZ study findings. J Prev Alzheimers Dis. 2023;10(3):595\u20139. https:\/\/doi.org\/10.14283\/jpad.2023.50.","journal-title":"J Prev Alzheimers Dis."},{"issue":"6","key":"633_CR85","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1002\/alz.12959","volume":"19","author":"RC Petersen","year":"2023","unstructured":"Petersen RC, Aisen PS, Andrews JS, Atri A, Matthews BR, Rentz DM, et al. Expectations and clinical meaningfulness of randomized controlled trials. Alzheimer\u2019s & Dementia. 2023;19(6):2730\u20136.","journal-title":"Alzheimer\u2019s & Dementia."},{"issue":"3","key":"633_CR86","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40120-023-00473-w","volume":"12","author":"AA Tahami Monfared","year":"2023","unstructured":"Tahami Monfared AA, Ye W, Sardesai A, Folse H, Chavan A, Aruffo E, et al. A path to improved Alzheimer\u2019s care: simulating long-term health outcomes of lecanemab in early Alzheimer\u2019s disease from the CLARITY AD trial. Neurol Ther. 2023;12(3):863\u201381.","journal-title":"Neurol Ther."},{"issue":"1","key":"633_CR87","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13195-022-00984-y","volume":"14","author":"SS Assun\u00e7\u00e3o","year":"2022","unstructured":"Assun\u00e7\u00e3o SS, Sperling RA, Ritchie C, Kerwin DR, Aisen PS, Lansdall C, et al. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2022;14(1):54.","journal-title":"Alzheimer\u2019s Res Ther."},{"issue":"1","key":"633_CR88","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/STROKEAHA.121.036873","volume":"53","author":"L Sveikata","year":"2022","unstructured":"Sveikata L, Charidimou A, Viswanathan A. Vessels sing their ARIAs: the role of vascular amyloid in the age of aducanumab. Stroke. 2022;53(1):298\u2013302.","journal-title":"Stroke"},{"issue":"20","key":"633_CR89","doi-asserted-by":"publisher","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","volume":"100","author":"F Alves","year":"2023","unstructured":"Alves F, Kalinowski P, Ayton S. Accelerated brain volume loss caused by anti-\u03b2-amyloid drugs: a systematic review and meta-analysis. Neurology. 2023;100(20):e2114\u201324.","journal-title":"Neurology"},{"issue":"12","key":"633_CR90","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1093\/brain\/awaa332","volume":"143","author":"C Sur","year":"2020","unstructured":"Sur C, Kost J, Scott D, Adamczuk K, Fox NC, Cummings JL, et al. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer\u2019s disease brain. Brain. 2020;143(12):3816\u201326.","journal-title":"Brain"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00633-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00633-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00633-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T09:24:44Z","timestamp":1705397084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00633-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["633"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00633-2","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"11 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jeffrey Cummings has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, Aprinoia, AriBio, Artery, Biogen, BioVie, Cassava, Cerecin, Diadem, EIP Pharma, Eisai, GemVax, Genentech, GAP Innovations, Janssen, Jocasta, Karuna, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, Suven, SynapseBio, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. Davis Cammann, Jayde Powell, Amanda Leisgang Osse, and Jingchun Chen have no disclosures to declare in relation to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funding was received specifically for the development of this manuscript. Production of the manuscript is consistent with the lead author\u2019s R35 award from the National Institute on Aging (NIA grant R35AG71476).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"No patient data are included in this article and all information is publicly available. No ethics approval is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No patients were included this this article. All information is available on ClinicalTrials.gov or derived from PubMed sources. No patient consent is required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to participate\/publish"}},{"value":"No database was developed for this article. All material cited is available on PubMed and cited in the references or derived from the publicly available registry ClinicalTrials.gov.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"No database was developed for this article. All material cited is available on PubMed and cited in the references or derived from the publicly available registry ClinicalTrials.gov.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to this article and approved the final manuscript. Each of the authors developed the section on at least one monoclonal antibody. Jeffrey Cummings conceived the article and produced the original outline. The outline was approved by all authors. Amanda Leisgang Osse managed the references and Mike de la Flor created the illustration.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}